APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologics CDMO

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Biologics CDMO Industry Growth and Trends Forecast to 2032

29 December 2025102 pages

Choose your research edition.

Industry ResearchBiologics CDMO Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics CDMO Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Biologics CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics CDMO Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics CDMO Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Biologics CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Biologics CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Biologics CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biologics CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Biologics CDMO include AGC, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, ICON Plc, Samsung Biologics, Toyobo, AbbVie, Lonza Group AG and Thermo Fisher Scientific, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Biologics CDMO market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Biologics CDMO market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Biologics CDMO market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Biologics CDMO.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Biologics CDMO market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Biologics CDMO Market by Company

AGC

Boehringer Ingelheim

Fujifilm Diosynth Biotechnologies

ICON Plc

Samsung Biologics

Toyobo

AbbVie

Lonza Group AG

Thermo Fisher Scientific

WuXi Biologics

Biologics CDMO Segment by Type

Biological Agent

Biosimilar Drug

Biologics CDMO Segment by Application

Cell Therapy

Drug Development

Others

Biologics CDMO Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biologics CDMO manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Biologics CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Biological Agent Table 2. Major Company of Biosimilar Drug Table 3. Global Biologics CDMO Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Biologics CDMO Sales by Type (2021-2026) & (K Units) Table 5. Global Biologics CDMO Sales Market Share in Volume by Type (2021-2026) Table 6. Global Biologics CDMO Sales by Type (2021-2026) & (US$ Million) Table 7. Global Biologics CDMO Sales Market Share in Value by Type (2021-2026) Table 8. Global Biologics CDMO Price by Type (2021-2026) & (US$/Unit) Table 9. Global Biologics CDMO Sales by Type (2027-2032) & (K Units) Table 10. Global Biologics CDMO Sales Market Share in Volume by Type (2027-2032) Table 11. Global Biologics CDMO Sales by Type (2027-2032) & (US$ Million) Table 12. Global Biologics CDMO Sales Market Share in Value by Type (2027-2032) Table 13. Global Biologics CDMO Price by Type (2027-2032) & (US$/Unit) Table 14. North America Biologics CDMO Sales by Type (2021-2026) & (K Units) Table 15. North America Biologics CDMO Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Biologics CDMO Sales by Type (2021-2026) & (K Units) Table 17. Europe Biologics CDMO Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Biologics CDMO Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Biologics CDMO Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Biologics CDMO Sales by Type (2021-2026) & (K Units) Table 21. Latin America Biologics CDMO Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Biologics CDMO Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Biologics CDMO Sales by Type (2021-2026) & (US$ Million) Table 24. Biologics CDMO Industry Trends Table 25. Biologics CDMO Industry Drivers Table 26. Biologics CDMO Industry Opportunities and Challenges Table 27. Biologics CDMO Industry Restraints Table 28. Global Biologics CDMO Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Biologics CDMO Revenue Market Share by Company (2021-2026) Table 30. Global Biologics CDMO Sales by Company (2021-2026) & (K Units) Table 31. Global Biologics CDMO Sales Share by Company (2021-2026) Table 32. Global Biologics CDMO Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Biologics CDMO Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Biologics CDMO Major Company Production Sites and Headquarters Table 35. Global Biologics CDMO Company, Product Type & Application Table 36. Global Biologics CDMO Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Biologics CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Biologics CDMO Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Biologics CDMO Sales by Region (2021-2026) & (K Units) Table 41. Global Biologics CDMO Sales Market Share in Volume by Region (2021-2026) Table 42. Global Biologics CDMO Sales by Region (2021-2026) & (US$ Million) Table 43. Global Biologics CDMO Sales Market Share in Value by Region (2021-2026) Table 44. Global Biologics CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Biologics CDMO Sales by Region (2027-2032) & (K Units) Table 46. Global Biologics CDMO Sales Market Share in Volume by Region (2027-2032) Table 47. Global Biologics CDMO Sales by Region (2027-2032) & (US$ Million) Table 48. Global Biologics CDMO Sales Market Share in Value by Region (2027-2032) Table 49. Global Biologics CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Biologics CDMO Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Biologics CDMO Sales by Application (2021-2026) & (K Units) Table 52. Global Biologics CDMO Sales Market Share in Volume by Application (2021-2026) Table 53. Global Biologics CDMO Sales by Application (2021-2026) & (US$ Million) Table 54. Global Biologics CDMO Sales Market Share in Value by Application (2021-2026) Table 55. Global Biologics CDMO Price by Application (2021-2026) & (US$/Unit) Table 56. Global Biologics CDMO Sales by Application (2027-2032) & (K Units) Table 57. Global Biologics CDMO Sales Market Share in Volume by Application (2027-2032) Table 58. Global Biologics CDMO Sales by Application (2027-2032) & (US$ Million) Table 59. Global Biologics CDMO Sales Market Share in Value by Application (2027-2032) Table 60. Global Biologics CDMO Price by Application (2027-2032) & (US$/Unit) Table 61. North America Biologics CDMO Sales by Application (2021-2026) & (K Units) Table 62. North America Biologics CDMO Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Biologics CDMO Sales by Application (2021-2026) & (K Units) Table 64. Europe Biologics CDMO Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Biologics CDMO Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Biologics CDMO Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Biologics CDMO Sales by Application (2021-2026) & (K Units) Table 68. Latin America Biologics CDMO Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Biologics CDMO Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Biologics CDMO Sales by Application (2021-2026) & (US$ Million) Table 71. AGC Company Information Table 72. AGC Business Overview Table 73. AGC Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. AGC Biologics CDMO Product Portfolio Table 75. AGC Recent Development Table 76. Boehringer Ingelheim Company Information Table 77. Boehringer Ingelheim Business Overview Table 78. Boehringer Ingelheim Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Boehringer Ingelheim Biologics CDMO Product Portfolio Table 80. Boehringer Ingelheim Recent Development Table 81. Fujifilm Diosynth Biotechnologies Company Information Table 82. Fujifilm Diosynth Biotechnologies Business Overview Table 83. Fujifilm Diosynth Biotechnologies Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Fujifilm Diosynth Biotechnologies Biologics CDMO Product Portfolio Table 85. Fujifilm Diosynth Biotechnologies Recent Development Table 86. ICON Plc Company Information Table 87. ICON Plc Business Overview Table 88. ICON Plc Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. ICON Plc Biologics CDMO Product Portfolio Table 90. ICON Plc Recent Development Table 91. Samsung Biologics Company Information Table 92. Samsung Biologics Business Overview Table 93. Samsung Biologics Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Samsung Biologics Biologics CDMO Product Portfolio Table 95. Samsung Biologics Recent Development Table 96. Toyobo Company Information Table 97. Toyobo Business Overview Table 98. Toyobo Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Toyobo Biologics CDMO Product Portfolio Table 100. Toyobo Recent Development Table 101. AbbVie Company Information Table 102. AbbVie Business Overview Table 103. AbbVie Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. AbbVie Biologics CDMO Product Portfolio Table 105. AbbVie Recent Development Table 106. Lonza Group AG Company Information Table 107. Lonza Group AG Business Overview Table 108. Lonza Group AG Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Lonza Group AG Biologics CDMO Product Portfolio Table 110. Lonza Group AG Recent Development Table 111. Thermo Fisher Scientific Company Information Table 112. Thermo Fisher Scientific Business Overview Table 113. Thermo Fisher Scientific Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Thermo Fisher Scientific Biologics CDMO Product Portfolio Table 115. Thermo Fisher Scientific Recent Development Table 116. WuXi Biologics Company Information Table 117. WuXi Biologics Business Overview Table 118. WuXi Biologics Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. WuXi Biologics Biologics CDMO Product Portfolio Table 120. WuXi Biologics Recent Development Table 121. North America Biologics CDMO Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 122. North America Biologics CDMO Sales by Country (2021-2026) & (K Units) Table 123. North America Biologics CDMO Sales Market Share by Country (2021-2026) Table 124. North America Biologics CDMO Sales Forecast by Country (2027-2032) & (K Units) Table 125. North America Biologics CDMO Sales Market Share Forecast by Country (2027-2032) Table 126. North America Biologics CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. North America Biologics CDMO Market Size by Country (2021-2026) & (US$ Million) Table 128. North America Biologics CDMO Market Share by Country (2021-2026) Table 129. North America Biologics CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. North America Biologics CDMO Market Share Forecast by Country (2027-2032) Table 131. Europe Biologics CDMO Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. Europe Biologics CDMO Sales by Country (2021-2026) & (K Units) Table 133. Europe Biologics CDMO Sales Market Share by Country (2021-2026) Table 134. Europe Biologics CDMO Sales Forecast by Country (2027-2032) & (K Units) Table 135. Europe Biologics CDMO Sales Market Share Forecast by Country (2027-2032) Table 136. Europe Biologics CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Europe Biologics CDMO Market Size by Country (2021-2026) & (US$ Million) Table 138. Europe Biologics CDMO Market Share by Country (2021-2026) Table 139. Europe Biologics CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Europe Biologics CDMO Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Biologics CDMO Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Biologics CDMO Sales by Country (2021-2026) & (K Units) Table 143. Asia-Pacific Biologics CDMO Sales Market Share by Country (2021-2026) Table 144. Asia-Pacific Biologics CDMO Sales Forecast by Country (2027-2032) & (K Units) Table 145. Asia-Pacific Biologics CDMO Sales Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific Biologics CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific Biologics CDMO Market Size by Country (2021-2026) & (US$ Million) Table 148. Asia-Pacific Biologics CDMO Market Share by Country (2021-2026) Table 149. Asia-Pacific Biologics CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Asia-Pacific Biologics CDMO Market Share Forecast by Country (2027-2032) Table 151. Latin America Biologics CDMO Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. Latin America Biologics CDMO Sales by Country (2021-2026) & (K Units) Table 153. Latin America Biologics CDMO Sales Market Share by Country (2021-2026) Table 154. Latin America Biologics CDMO Sales Forecast by Country (2027-2032) & (K Units) Table 155. Latin America Biologics CDMO Sales Market Share Forecast by Country (2027-2032) Table 156. Latin America Biologics CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Latin America Biologics CDMO Market Size by Country (2021-2026) & (US$ Million) Table 158. Latin America Biologics CDMO Market Share by Country (2021-2026) Table 159. Latin America Biologics CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Latin America Biologics CDMO Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Biologics CDMO Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Biologics CDMO Sales by Country (2021-2026) & (K Units) Table 163. Middle East and Africa Biologics CDMO Sales Market Share by Country (2021-2026) Table 164. Middle East and Africa Biologics CDMO Sales Forecast by Country (2027-2032) & (K Units) Table 165. Middle East and Africa Biologics CDMO Sales Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa Biologics CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa Biologics CDMO Market Size by Country (2021-2026) & (US$ Million) Table 168. Middle East and Africa Biologics CDMO Market Share by Country (2021-2026) Table 169. Middle East and Africa Biologics CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Middle East and Africa Biologics CDMO Market Share Forecast by Country (2027-2032) Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. Biologics CDMO Distributors List Table 174. Biologics CDMO Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Biologics CDMO Image Figure 2. Global Biologics CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Biologics CDMO Sales (2021-2032) & (K Units) Figure 5. Biological Agent Image Figure 6. Global Biological Agent Sales YoY Growth (2021-2032) & (K Units) Figure 7. Biosimilar Drug Image Figure 8. Global Biosimilar Drug Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Biologics CDMO Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Biologics CDMO Market Share by Type 2025 VS 2032 Figure 11. North America Biologics CDMO Sales Market Share in Volume by Type in 2025 Figure 12. North America Biologics CDMO Sales Market Share in Value by Type in 2025 Figure 13. Europe Biologics CDMO Sales Market Share in Volume by Type in 2025 Figure 14. Europe Biologics CDMO Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Biologics CDMO Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Biologics CDMO Sales Market Share in Value by Type in 2025 Figure 17. Latin America Biologics CDMO Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Biologics CDMO Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Biologics CDMO Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Biologics CDMO Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Biologics CDMO Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Cell Therapy Image Figure 24. Global Cell Therapy Sales YoY Growth (2021-2032) & (K Units) Figure 25. Drug Development Image Figure 26. Global Drug Development Sales YoY Growth (2021-2032) & (K Units) Figure 27. Others Image Figure 28. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Biologics CDMO Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Biologics CDMO Market Share by Application 2025 VS 2032 Figure 31. North America Biologics CDMO Sales Market Share in Volume by Application in 2025 Figure 32. North America Biologics CDMO Sales Market Share in Value by Application in 2025 Figure 33. Europe Biologics CDMO Sales Market Share in Volume by Application in 2025 Figure 34. Europe Biologics CDMO Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Biologics CDMO Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Biologics CDMO Sales Market Share in Value by Application in 2025 Figure 37. Latin America Biologics CDMO Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Biologics CDMO Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Biologics CDMO Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Biologics CDMO Sales Market Share in Value by Application in 2025 Figure 41. North America Biologics CDMO Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Biologics CDMO Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Biologics CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Biologics CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Biologics CDMO Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Biologics CDMO Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Biologics CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Biologics CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Biologics CDMO Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Biologics CDMO Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Biologics CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Biologics CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Biologics CDMO Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Biologics CDMO Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Biologics CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Biologics CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Biologics CDMO Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Biologics CDMO Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Biologics CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Biologics CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Biologics CDMO Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Biologics CDMO Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Biological Agent
  • Biosimilar Drug
Applications
  • Cell Therapy
  • Drug Development
  • Others
Companies covered
  • AGC
  • Boehringer Ingelheim
  • Fujifilm Diosynth Biotechnologies
  • ICON Plc
  • Samsung Biologics
  • Toyobo
  • AbbVie
  • Lonza Group AG
  • Thermo Fisher Scientific
  • WuXi Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biologics CDMO Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Biologics CDMO Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Biologics CDMO Market by Type
  6. 1.3.1 Biological Agent
  7. 1.3.2 Biosimilar Drug
  8. 1.4 Global Biologics CDMO Market Size by Type
  9. 1.4.1 Global Biologics CDMO Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Biologics CDMO Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Biologics CDMO Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Biologics CDMO Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Biologics CDMO Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Biologics CDMO Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Biologics CDMO Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Biologics CDMO Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Biologics CDMO Industry Trends
  2. 2.2 Biologics CDMO Industry Drivers
  3. 2.3 Biologics CDMO Industry Opportunities and Challenges
  4. 2.4 Biologics CDMO Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Biologics CDMO Revenue (2021-2026)
  2. 3.2 Global Top Players by Biologics CDMO Sales (2021-2026)
  3. 3.3 Global Top Players by Biologics CDMO Price (2021-2026)
  4. 3.4 Global Biologics CDMO Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biologics CDMO Major Company Production Sites & Headquarters
  6. 3.6 Global Biologics CDMO Company, Product Type & Application
  7. 3.7 Global Biologics CDMO Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biologics CDMO Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biologics CDMO Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biologics CDMO Tier 1, Tier 2, and Tier 3
4 Biologics CDMO Regional Status and Outlook
  1. 4.1 Global Biologics CDMO Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Biologics CDMO Historic Market Size by Region
  3. 4.2.1 Global Biologics CDMO Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Biologics CDMO Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Biologics CDMO Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Biologics CDMO Forecasted Market Size by Region
  7. 4.3.1 Global Biologics CDMO Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Biologics CDMO Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Biologics CDMO Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Biologics CDMO by Application
  1. 5.1 Biologics CDMO Market by Application
  2. 5.1.1 Cell Therapy
  3. 5.1.2 Drug Development
  4. 5.1.3 Others
  5. 5.2 Global Biologics CDMO Market Size by Application
  6. 5.2.1 Global Biologics CDMO Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Biologics CDMO Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Biologics CDMO Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Biologics CDMO Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Biologics CDMO Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Biologics CDMO Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Biologics CDMO Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Biologics CDMO Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 AGC
  2. 6.1.1 AGC Company Information
  3. 6.1.2 AGC Business Overview
  4. 6.1.3 AGC Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 AGC Biologics CDMO Product Portfolio
  6. 6.1.5 AGC Recent Developments
  7. 6.2 Boehringer Ingelheim
  8. 6.2.1 Boehringer Ingelheim Company Information
  9. 6.2.2 Boehringer Ingelheim Business Overview
  10. 6.2.3 Boehringer Ingelheim Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Boehringer Ingelheim Biologics CDMO Product Portfolio
  12. 6.2.5 Boehringer Ingelheim Recent Developments
  13. 6.3 Fujifilm Diosynth Biotechnologies
  14. 6.3.1 Fujifilm Diosynth Biotechnologies Company Information
  15. 6.3.2 Fujifilm Diosynth Biotechnologies Business Overview
  16. 6.3.3 Fujifilm Diosynth Biotechnologies Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Fujifilm Diosynth Biotechnologies Biologics CDMO Product Portfolio
  18. 6.3.5 Fujifilm Diosynth Biotechnologies Recent Developments
  19. 6.4 ICON Plc
  20. 6.4.1 ICON Plc Company Information
  21. 6.4.2 ICON Plc Business Overview
  22. 6.4.3 ICON Plc Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 ICON Plc Biologics CDMO Product Portfolio
  24. 6.4.5 ICON Plc Recent Developments
  25. 6.5 Samsung Biologics
  26. 6.5.1 Samsung Biologics Company Information
  27. 6.5.2 Samsung Biologics Business Overview
  28. 6.5.3 Samsung Biologics Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Samsung Biologics Biologics CDMO Product Portfolio
  30. 6.5.5 Samsung Biologics Recent Developments
  31. 6.6 Toyobo
  32. 6.6.1 Toyobo Company Information
  33. 6.6.2 Toyobo Business Overview
  34. 6.6.3 Toyobo Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Toyobo Biologics CDMO Product Portfolio
  36. 6.6.5 Toyobo Recent Developments
  37. 6.7 AbbVie
  38. 6.7.1 AbbVie Company Information
  39. 6.7.2 AbbVie Business Overview
  40. 6.7.3 AbbVie Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 AbbVie Biologics CDMO Product Portfolio
  42. 6.7.5 AbbVie Recent Developments
  43. 6.8 Lonza Group AG
  44. 6.8.1 Lonza Group AG Company Information
  45. 6.8.2 Lonza Group AG Business Overview
  46. 6.8.3 Lonza Group AG Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Lonza Group AG Biologics CDMO Product Portfolio
  48. 6.8.5 Lonza Group AG Recent Developments
  49. 6.9 Thermo Fisher Scientific
  50. 6.9.1 Thermo Fisher Scientific Company Information
  51. 6.9.2 Thermo Fisher Scientific Business Overview
  52. 6.9.3 Thermo Fisher Scientific Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Thermo Fisher Scientific Biologics CDMO Product Portfolio
  54. 6.9.5 Thermo Fisher Scientific Recent Developments
  55. 6.10 WuXi Biologics
  56. 6.10.1 WuXi Biologics Company Information
  57. 6.10.2 WuXi Biologics Business Overview
  58. 6.10.3 WuXi Biologics Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 WuXi Biologics Biologics CDMO Product Portfolio
  60. 6.10.5 WuXi Biologics Recent Developments
7 North America by Country
  1. 7.1 North America Biologics CDMO Sales by Country
  2. 7.1.1 North America Biologics CDMO Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Biologics CDMO Sales by Country (2021-2026)
  4. 7.1.3 North America Biologics CDMO Sales Forecast by Country (2027-2032)
  5. 7.2 North America Biologics CDMO Market Size by Country
  6. 7.2.1 North America Biologics CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Biologics CDMO Market Size by Country (2021-2026)
  8. 7.2.3 North America Biologics CDMO Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Biologics CDMO Sales by Country
  2. 8.1.1 Europe Biologics CDMO Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Biologics CDMO Sales by Country (2021-2026)
  4. 8.1.3 Europe Biologics CDMO Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Biologics CDMO Market Size by Country
  6. 8.2.1 Europe Biologics CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Biologics CDMO Market Size by Country (2021-2026)
  8. 8.2.3 Europe Biologics CDMO Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Biologics CDMO Sales by Country
  2. 9.1.1 Asia-Pacific Biologics CDMO Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Biologics CDMO Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Biologics CDMO Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Biologics CDMO Market Size by Country
  6. 9.2.1 Asia-Pacific Biologics CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Biologics CDMO Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Biologics CDMO Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Biologics CDMO Sales by Country
  2. 10.1.1 South America Biologics CDMO Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Biologics CDMO Sales by Country (2021-2026)
  4. 10.1.3 South America Biologics CDMO Sales Forecast by Country (2027-2032)
  5. 10.2 South America Biologics CDMO Market Size by Country
  6. 10.2.1 South America Biologics CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Biologics CDMO Market Size by Country (2021-2026)
  8. 10.2.3 South America Biologics CDMO Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Biologics CDMO Sales by Country
  2. 11.1.1 Middle East and Africa Biologics CDMO Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Biologics CDMO Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Biologics CDMO Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Biologics CDMO Market Size by Country
  6. 11.2.1 Middle East and Africa Biologics CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Biologics CDMO Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Biologics CDMO Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Biologics CDMO Value Chain Analysis
  2. 12.1.1 Biologics CDMO Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Biologics CDMO Production Mode & Process
  7. 12.2 Biologics CDMO Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Biologics CDMO Distributors
  10. 12.2.3 Biologics CDMO Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst